Development, Evaluation, and Application of an In Silico Model for Antimalarial Drug Treatment and Failure

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Antimicrobial Agents and Chemotherapy

• Publication date

  2011-05-02

• Fields of study

  Medicine, Computer Science

• Identifiers
  DOI 10.1128/AAC.01712-10PMID 21537019PMCID PMC3122393
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Safety and efficacy of dihydroartemisinin-piperaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Zambian children

  2011cited by this paper
• Plasmodium falciparum genome-wide scans for positive selection, recombination hot spots and resistance to antimalarial drugs

  2010cited by this paper
• A randomized trial of artesunate mefloquine versus artemether lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Senegalese children.

  2010cited by this paper
• Mitochondrial Electron Transport Inhibition and Viability of Intraerythrocytic Plasmodium falciparum

  2010cited by this paper
• Treatment with coartem (artemether-lumefantrine) in Papua New Guinea.

  2010cited by this paper
• Guidelines for the treatment of malaria

  2010cited by this paper
• Artemisinin resistance: current status and scenarios for containment

  2010cited by this paper
• Malaria's drug miracle in danger.

  2010cited by this paper
• Artemisinin‐induced dormancy in plasmodium falciparum: duration, recovery rates, and implications in treatment failure.

  2010cited by this paper
• Artemisinin resistance: current status and scenarios for containment

  2010cited by this paper
• The pharmacokinetics of artemether and lumefantrine in pregnant women with uncomplicated falciparum malaria

  2009cited by this paper
• Malaria control--addressing challenges to ambitious goals.

  2009cited by this paper
• Pharmacokinetics and Ex Vivo Pharmacodynamic Antimalarial Activity of Dihydroartemisinin-Piperaquine in Patients with Uncomplicated Falciparum Malaria in Vietnam

  2009cited by this paper
• Artemisinin resistance could endanger fight against malaria

  2009cited by this paper
• In vivo selection of Plasmodium falciparum parasites carrying the chloroquine-susceptible pfcrt K76 allele after treatment with artemether-lumefantrine in Africa.

  2009cited by this paper
• Therapeutic efficacy of artemether-lumefantrine in uncomplicated falciparum malaria in India

  2009cited by this paper
• Artemisinin resistance in Plasmodium falciparum malaria.

  2009cited by this paper
• A randomized trial of artesunate-mefloquine versus artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Mali.

  2008cited by this paper
• Simplified antimalarial therapeutic monitoring: using the day-7 drug level?

  2008cited by this paper
• A trial of combination antimalarial therapies in children from Papua New Guinea.

  2008cited by this paper
• Methods and techniques for clinical trials on antimalarial drug efficacy: genotyping to identify parasite populations

  2008cited by this paper
• Declining Artesunate-Mefloquine Efficacy against Falciparum Malaria on the Cambodia–Thailand Border

  2008cited by this paper
• Spread of anti-malarial drug resistance: Mathematical model with implications for ACT drug policies

  2008cited by this paper
• Chloroquine Is Grossly Overdosed and Overused but Well Tolerated in Guinea-Bissau

  2008cited by this paper
• Evidence of artemisinin-resistant malaria in western Cambodia.

  2008cited by this paper
• Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs

  2008cited by this paper
• Pharmacokinetics and Bioequivalence Evaluation of Two Fixed-Dose Tablet Formulations of Dihydroartemisinin and Piperaquine in Vietnamese Subjects

  2008cited by this paper
• Pharmacokinetic Determinants of the Window of Selection for Antimalarial Drug Resistance

  2008cited by this paper
• Does the drug sensitivity of malaria parasites depend on their virulence?

  2008cited by this paper
• Pharmacokinetics and metabolism of the antimalarial piperaquine after intravenous and oral single doses to the rat.

  2008cited by this paper
• Antimalarial dosing regimens and drug resistance.

  2008cited by this paper
• Mechanism-based pharmacokinetic–pharmacodynamic modeling of antimicrobial drug effects

  2007influential reference
• Impact of Transmission Intensity on the Accuracy of Genotyping To Distinguish Recrudescence from New Infection in Antimalarial Clinical Trials

  2007cited by this paper
• Phase III Trial of Albumin in Malaria Still Lacks Scientific Justification

  2007cited by this paper
• Artemether-Lumefantrine versus Dihydroartemisinin-Piperaquine for Treatment of Malaria: A Randomized Trial

  2007cited by this paper
• A Randomised Controlled Trial to Assess the Efficacy of Dihydroartemisinin-Piperaquine for the Treatment of Uncomplicated Falciparum Malaria in Peru

  2007influential reference
• Antimalarial drugs and pregnancy: safety, pharmacokinetics, and pharmacovigilance.

  2007cited by this paper
• The role of pfmdr1 in Plasmodium falciparum tolerance to artemether‐lumefantrine in Africa

  2007cited by this paper
• In vitro antimalarial drug susceptibility and pfcrt mutation among fresh Plasmodium falciparum isolates from the Lao PDR (Laos).

  2007cited by this paper
• Antimalarial Drug Therapy: The Role of Parasite Biology and Drug Resistance

  2006cited by this paper
• Supervised versus unsupervised antimalarial treatment with six-dose artemether-lumefantrine: pharmacokinetic and dosage-related findings from a clinical trial in Uganda

  2006cited by this paper
• Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies

  2006cited by this paper
• Use of weight-for-age-data to optimize tablet strength and dosing regimens for a new fixed-dose artesunate-amodiaquine combination for treating falciparum malaria.

  2006cited by this paper
• Population Pharmacokinetics of Artesunate and Dihydroartemisinin following Intra-Rectal Dosing of Artesunate in Malaria Patients

  2006cited by this paper
• An immigration–death model to estimate the duration of malaria infection when detectability of the parasite is imperfect

  2005cited by this paper
• Coartem (artemether-lumefantrine) in Africa: the beginning of the end?

  2005cited by this paper
• The disposition of oral amodiaquine in Papua New Guinean children with falciparum malaria.

  2005cited by this paper
• In vivo selection of Plasmodium falciparum pfmdr1 86N coding alleles by artemether-lumefantrine (Coartem).

  2005cited by this paper
• Antimicrobial Therapy and Vaccines; Volume II: Antimicrobial Agents

  2005cited by this paper
• Are Transporter Genes Other than the Chloroquine Resistance Locus (pfcrt) and Multidrug Resistance Gene (pfmdr) Associated with Antimalarial Drug Resistance?

  2005cited by this paper
• Artesunate combinations for treatment of malaria: meta-analysis.

  2004cited by this paper
• Evolution of Resistance to Sulfadoxine-Pyrimethamine in Plasmodium falciparum

  2004cited by this paper
• Population pharmacokinetics of piperaquine in adults and children with uncomplicated falciparum or vivax malaria.

  2003cited by this paper
• Treatment of uncomplicated falciparum malaria in southern Vietnam: can chloroquine or sulfadoxine-pyrimethamine be reintroduced in combination with artesunate?

  2003cited by this paper
• Treatment of children with Plasmodium falciparum malaria with chloroquine in Guinea-Bissau.

  2002influential reference
• Pharmacokinetic Interactions of Antimalarial Agents

  2001cited by this paper
• Pharmacokinetic-pharmacodynamic modelling of the anti-malarial activity of mefloquine

  2001cited by this paper
• Mathematical modelling of the chemotherapy of Plasmodium falciparum malaria with artesunate: postulation of ‘dormancy’, a partial cytostatic effect of the drug, and its implication for treatment regimens

  2000cited by this paper
• Mefloquine Pharmacokinetic-Pharmacodynamic Models: Implications for Dosing and Resistance

  2000cited by this paper
• Pharmacokinetics and Pharmacodynamics of Lumefantrine (Benflumetol) in Acute Falciparum Malaria

  2000cited by this paper
• Plasmodium falciparum antimalarial drug susceptibility on the north-western border of Thailand during five years of extensive use of artesunate-mefloquine.

  2000cited by this paper
• Antimalarial drug resistance and combination chemotherapy.

  1999cited by this paper
• Binding of artemether and lumefantrine to plasma proteins and erythrocytes.

  1999cited by this paper
• Modelling the chloroquine chemotherapy of falciparum malaria: the value of spacing a split dose

  1998cited by this paper
• The dynamics of drug action on the within-host population growth of infectious agents: melding pharmacokinetics with pathogen population dynamics.

  1998cited by this paper
• Assessment of the pharmacodynamic properties of antimalarial drugs in vivo

  1997cited by this paper
• Clinical Pharmacokinetics and Metabolism of Chloroquine

  1996cited by this paper
• Pharmacokinetics of Quinine, Chloroquine and Amodiaquine

  1996cited by this paper
• Antimalarial 4‐aminoquinolines: mode of action and pharmacokinetics

  1994cited by this paper
• Antimalarial pharmacokinetics and treatment regimens.

  1992cited by this paper
• Pseudomonas pseudomallei: danger in the paddy fields.

  1991cited by this paper
• Chloroquine resistant Plasmodium falciparum malaria in Guinea-Bissau.

  1991influential reference
• Application of a new approach for the quantitation of drug synergism to the combination of cis-diamminedichloroplatinum and 1-beta-D-arabinofuranosylcytosine.

  1990cited by this paper
• Chloroquine resistant Plasmodium falciparum malaria in Namibia.

  1984cited by this paper
• Quinine disposition kinetics.

  1983cited by this paper
• The employment of combinations of drugs in the chemotherapy of neoplasia: a review.

  1957cited by this paper

• Classification of outcomes in antimalarial therapeutic efficacy studies with Aster

  2025cites this paper
• Seasonal malaria chemoprevention and the spread of Plasmodium falciparum quintuple mutant parasites resistant to sulfadoxine-pyrimethamine: a modelling study

  2023cites this paper
• Design and selection of drug properties to increase the public health impact of next-generation seasonal malaria chemoprevention: a modelling study

  2023cites this paper
• The influence of biological, epidemiological, and treatment factors on the establishment and spread of drug-resistant Plasmodium falciparum

  2022influential citation
• Effectiveness of intermittent preventive treatment in pregnancy with sulfadoxine-pyrimethamine: An in silico pharmacological model

  2020influential citation
• A Computer Modelling Approach To Evaluate the Accuracy of Microsatellite Markers for Classification of Recurrent Infections during Routine Monitoring of Antimalarial Drug Efficacy

  2020influential citation
• Population Pharmacokinetics and Pharmacodynamics of Chloroquine in a Plasmodium vivax Volunteer Infection Study

  2020cites this paper
• Evaluating accuracy of microsatellite markers for classification of recurrent infections during routine monitoring of anti-malarial drug efficacy: A computer modelling approach

  2020cites this paper
• Outcome Impacts Due to Pathogen-Specific Antimicrobial Resistance: A Narrative Review of Published Literature

  2020cites this paper
• The Role of Clinical Pharmacology in Chemotherapy of Multidrug‐Resistant Plasmodium falciparum

  2020cites this paper
• Improving Methods for Analyzing Antimalarial Drug Efficacy Trials: Molecular Correction Based on Length-Polymorphic Markers msp-1, msp-2, and glurp

  2019cites this paper
• Evaluating artesunate-amodiaquine deployment, efficacy and safety: an in silico pharmacological model

  2019cites this paper
• Investigating the Efficacy of Triple Artemisinin-Based Combination Therapies for Treating Plasmodium falciparum Malaria Patients Using Mathematical Modeling

  2018cites this paper
• In Silico Investigation of the Decline in Clinical Efficacy of Artemisinin Combination Therapies Due to Increasing Artemisinin and Partner Drug Resistance

  2018cites this paper
• Investigating the Efficacy of Triple Artemisinin-Based Combination Therapies for Treating Plasmodium falciparum Malaria Patients Using Mathematical Modeling

  2018cites this paper
• The Impact of Antimalarial Use on the Emergence and Transmission of Plasmodium falciparum Resistance: A Scoping Review of Mathematical Models

  2017cites this paper
• malERA: An updated research agenda for malaria elimination and eradication

  2017cites this paper
• malERA: An updated research agenda for combination interventions and modelling in malaria elimination and eradication

  2017cites this paper
• Assessing the impact of imperfect adherence to artemether-lumefantrine on malaria treatment outcomes using within-host modelling

  2017cites this paper
• Antimalarial efficacy of MMV390048, an inhibitor of Plasmodium phosphatidylinositol 4-kinase

  2017cites this paper
• OptiMal-PK: an internet-based, user-friendly interface for the mathematical-based design of optimized anti-malarial treatment regimens

  2016influential citation
• Quantifying the pharmacology of antimalarial drug combination therapy

  2016cites this paper
• Operational strategies of anti-malarial drug campaigns for malaria elimination in Zambia’s southern province: a simulation study

  2016cites this paper
• Incorporating Stage Specific Drug Action into Pharmacological 1 Modelling of Antimalarial Drug Treatment 2 3

  2016cites this paper
• Incorporating Stage-Specific Drug Action into Pharmacological Modeling of Antimalarial Drug Treatment

  2016cites this paper
• Altering Antimalarial Drug Regimens May Dramatically Enhance and Restore Drug Effectiveness

  2015cites this paper
• How Robust Are Malaria Parasite Clearance Rates as Indicators of Drug Effectiveness and Resistance?

  2015influential citation
• Modelling the time course of antimalarial parasite killing: a tour of animal and human models, translation and challenges

  2015cites this paper
• Running title : Enhancing and restoring antimalarial effectiveness

  2015influential citation
• Triaminopyrimidine is a fast-killing and long-acting antimalarial clinical candidate

  2015cites this paper
• Measuring windows of selection for anti-malarial drug treatments

  2015cites this paper
• Evolution from double to triple-antimalarial drug combinations.

  2015cites this paper
• Optimizing the programmatic deployment of the anti-malarials artemether-lumefantrine and dihydroartemisinin-piperaquine using pharmacological modelling

  2014cites this paper
• Modeling Within-Host Effects of Drugs on Plasmodium falciparum Transmission and Prospects for Malaria Elimination

  2014cites this paper
• Pharmacological considerations in the design of anti-malarial drug combination therapies – is matching half-lives enough?

  2014influential citation
• Title : Improving the role and contribution of pharmacokinetic analyses in antimalarial drug 1 clinical trials 2 3 4 Running Title : Pharmacokinetics in antimalarial drug trials

  2014cites this paper
• Making the Most of Clinical Data: Reviewing the Role of Pharmacokinetic-Pharmacodynamic Models of Anti-malarial Drugs

  2014cites this paper
• Predicting the parasite killing effect of artemisinin combination therapy in a murine malaria model.

  2014cites this paper
• Improving the Role and Contribution of Pharmacokinetic Analyses in Antimalarial Drug Clinical Trials

  2014cites this paper
• Pharmacological modelling to investigate antimalarial drug treatment

  2013influential citation
• Pharmacokinetic and pharmacodynamic considerations 1 in antimalarial dose optimization

  2013cites this paper
• Improving Pharmacokinetic-Pharmacodynamic Modeling to Investigate Anti-Infective Chemotherapy with Application to the Current Generation of Antimalarial Drugs

  2013cites this paper
• Pharmacokinetic and Pharmacodynamic Considerations in Antimalarial Dose Optimization

  2013cites this paper
• Analysing malaria drug trials on a per‐individual or per‐clone basis: a comparison of methods

  2013cites this paper
• Predicting the cost-effectiveness of strategies for case management of "plasmodium falciparum" malaria in Sub-Saharan Africa

  2013cites this paper
• An in silico drug treatment model to assess the robustness of regional age-based dosing regimens for artemisinin-based combination therapies

  2012cites this paper
• Mechanism-Based Model of Parasite Growth and Dihydroartemisinin Pharmacodynamics in Murine Malaria

  2012cites this paper
• Estimating the window of selection of antimalarial drugs using field data

  2012cites this paper